DynamX Medical is developing a biopsy triaging system that aims to identify healthy and benign tissue specimens with high accuracy within seconds.
DynamX Medical Ltd was set up to commercialise research into the application of infrared spectroscopy to the diagnosis of cancer. The Company is developing a system that aims to enable rapid, accurate point-of-care screening of biopsies for pre-cancer/cancer.
The Company suggests that this will save time and money on more complex analyses and reduce time to diagnosis for both healthy and pre-cancer/cancer patients.
DynamX Medical’s flagship product is the biopsy triaging system, DynamX-Bx. This comprises DynamX software, which carries the unique patent-pending diagnostic algorithm and a user interface, combined with a commercially available infrared spectrometer. The system has a small footprint (approx. the size of a large laptop), can be installed near-patient and can be operated with minimal training.
|Product||Life sciences EIS|
|Aim of funding||Growth|
|HMRC Advanced Assurance received||Yes|
|Envisaged investor exit||IPO or Trade Sale|
|Targeted return||In excess of 3-5x invested|